{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:10:14Z","timestamp":1777479014963,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2012,7,15]],"date-time":"2012-07-15T00:00:00Z","timestamp":1342310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:p>\n                    Desirudin, a subcutaneously (SC) administered direct thrombin inhibitor, is indicated for prevention of venous thromboembolic events (VTEs) after total joint replacement surgery. DESIR-ABLE (multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation) was a multicenter, open-label, single-arm study of hospitalized patients requiring VTE protection designed to extend the safety profile for desirudin to include a broad population of perioperative\/critically ill patients. The primary end point was major bleeding. A total of 516 patients undergoing major surgery (378, 73%) or who were medically ill with prolonged immobility (138, 27%) were enrolled at 19 centers and received desirudin 15 mg Q12H. Many patients had high-risk features for bleeding and thrombosis such as thrombocytopenia (&lt;100\u00a0\u00d7\u00a010\n                    <jats:sup>9<\/jats:sup>\n                    \/mL, n = 50), severe obesity (body mass index &gt;35, n = 145), and renal impairment (creatinine clearance &lt;60 mL\/min, n = 292). There were no major bleeds and no VTE-related deaths in this study. The DESIR-ABLE demonstrated the safety of desirudin in critically ill perioperative and medical patients. Trials in specific surgical or medically ill patients are needed to confirm these findings.\n                  <\/jats:p>","DOI":"10.1177\/1076029612452779","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T11:23:55Z","timestamp":1342524235000},"page":"418-423","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Multicenter Trial of Desirudin for the Prophylaxis of Thrombosis"],"prefix":"10.1177","volume":"19","author":[{"given":"Sergio D.","family":"Bergese","sequence":"first","affiliation":[{"name":"The Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold S.","family":"Minkowitz","sequence":"additional","affiliation":[{"name":"Memorial Hermann Memorial City Medical Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Arpino","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Sane","sequence":"additional","affiliation":[{"name":"Virginia Tech Carilion School of Medicine and Research Center, Roanoke, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,7,15]]},"reference":[{"key":"bibr1-1076029612452779","unstructured":"Heparin for injection [package insert]. Deerfield, IL: Baxter; 2009."},{"key":"bibr2-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.338S"},{"key":"bibr3-1076029612452779","unstructured":"Iprivask [package insert]. Hunt Valley, MD: Canyon Pharmaceuticals, Inc; 2009."},{"key":"bibr4-1076029612452779","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060030-00012"},{"key":"bibr5-1076029612452779","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-199703000-00002"},{"key":"bibr6-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711063371901"},{"key":"bibr7-1076029612452779","unstructured":"Enoxaparin [package insert ]. Bridgewater, NJ: Sanofi-Aventis; 2009."},{"key":"bibr8-1076029612452779","unstructured":"Fondaparinux [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2010."},{"key":"bibr9-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.65"},{"key":"bibr10-1076029612452779","first-page":"A310","author":"Wang TY","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"bibr11-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0677"},{"key":"bibr12-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-010-0485-1"},{"key":"bibr13-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181f65503"},{"key":"bibr14-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1938"},{"key":"bibr15-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000066696.57519.AF"},{"key":"bibr16-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.11.007"},{"key":"bibr17-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2006.12.011"},{"issue":"1","key":"bibr18-1076029612452779","first-page":"132","volume":"94","author":"Greinacher A","year":"2005","journal-title":"Thromb Haemost"},{"key":"bibr19-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2010.06.002"},{"key":"bibr20-1076029612452779","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1538-7836.2011.04369.x","volume":"9","author":"Jaffer A","year":"2011","journal-title":"J Thromb Haemost"},{"key":"bibr21-1076029612452779","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.2009.97"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029612452779","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1076029612452779","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029612452779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:04:35Z","timestamp":1777385075000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1076029612452779"}},"subtitle":["An Alternative to Heparin-Based Anticoagulation (DESIR-ABLE)"],"short-title":[],"issued":{"date-parts":[[2012,7,15]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1177\/1076029612452779"],"URL":"https:\/\/doi.org\/10.1177\/1076029612452779","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,15]]}}}